NCT02935257View on ClinicalTrials.gov

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 29, 2017

Primary Completion Date

August 15, 2024

Study Completion Date

December 31, 2033

Conditions
Leukemia, Lymphoblastic, Acute, Lymphoma
Interventions
BIOLOGICAL

CD19CAT-41BBZ CAR T-cells

Infusion with CD19CAT-41BBZ CAR T-cells

Trial Locations (1)

Unknown

University College London Hospital, London

All Listed Sponsors
lead

University College, London

OTHER